晚期非小细胞肺癌一线治疗策略的选择

Choice of first-line treatment strategy for advanced non-small cell lung cancer

肺癌的发病率及死亡率均居我国恶性肿瘤的首位,且以晚期非小细胞肺癌(NSCLC)占有的比例为高。随着分子检测手段的进步,靶向及免疫治疗药物层出不穷,临床研究日益深入,为晚期NSCLC的治疗提供了更多的选择,但同时对于一线治疗策略的精准把握也带来了严峻的挑战,本文以驱动基因的表达情况为主线,对晚期NSCLC国内外临床研究进行总结,以期在循证医学指导下探究最佳一线治疗策略,最大程度地延长患者的生存期,提高生存质量。

The incidence and mortality of lung cancer rank first in China’s malignant tumors,and the proportion of advanced non-small cell lung cancer(NSCLC)is high.With the advancement of molecular detection methods,targeted and immunotherapeutic drugs emerge in an endless stream,and the clinical research is increasingly deep,providing more choices for the treatment of advanced NSCLC,but at the same time,the precise grasp of the first-line treatment strategy also brings severe challenges.In this paper,based on the expression of driver genes,the clinical research of advanced NSCLC at home and abroad is summarized,in order to explore the best first-line treatment strategy under the guidance of evidence-based medicine,to maximize the survival of patients and improve the quality of life.